Incretin therapy is a treatment for type 2 diabetes (T2DM) affected by heart failure (HF). In
this study the investigators will recruit T2DM patients affected by HF with depressed
ejection fraction and treated by Cardiac resynchronization therapy (CRT). These patients will
randomly be treated by incretin v/s conventional hypoglicemic drugs. In this patients
investigators will report at follow up CRT-d responders rate, mortality, and hospital
admission for HF worsening. Incretin may reduce hospital admissions for HF in T2DM v/s
conventional hypoglicemic drugs.